Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zejula
Pharma
GSK trial result mirrors Merck's problem in ovarian cancer
Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
Angus Liu
Dec 20, 2024 10:46am
Pfizer targets broad Talzenna label in prostate cancer
Oct 10, 2024 10:18am
ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint
Sep 14, 2024 8:45am
GSK blows Jemperli marching brass against Keytruda with new nod
Aug 1, 2024 3:00pm
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
Apr 24, 2024 8:23am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am
